TO EVALUATE EFFICACY AND SAFETY OF RUPATADINE, BILASTINE, AND LEVOCETRIZINE IN ALLERGIC RHINITIS AT TERITARY CARE HOSPITAL, TELANGANA
DOI:
https://doi.org/10.22159/ajpcr.2021.v14i12.43427Keywords:
Allergic rhinitis, Bilastine, Levocetirizine, Rupatadine, Total nasal symptom score, Absolute eosinophil countsAbstract
Objective: Allergic rhinitis (AR) is a heterogeneous disorder characterized by symptoms – sneezing, itching, nasal congestion, and rhinorrhea. The aim of the study is to evaluate the efficacy and safety of rupatadine, bilastine, and levocetirizine in AR.
Methods: A prospective, open-label, comparative study was conducted at the Government ENT Hospital, Hyderabad, Telangana. Ninety patients diagnosed with AR were randomized, of whom Group 1 received oral tab. bilastine 20 mg once daily, Group 2 received oral tab. levocetirizine 5 mg once daily, and Group 3 received oral tab. rupatadine with a dose of 10 mg once daily for 2 weeks. The reduction in total nasal symptom score (TNSS) and absolute eosinophil counts (AECs) was compared with baseline and at 2 weeks. Safety was assessed according to adverse events reported during the study period. An analysis of variance was used as a test of significance for the three groups.
Results: Overall, 90 cases were included in the study, with 48% of males and 52% of females. All three drugs significantly reduced the TNSS and AEC after treatment compared to before treatment (p<0.05). The mean difference in TNSS and AEC showed no statistically significant difference among the three groups (TNSS: p>0.908 and AEC: p>0.967). In terms of safety, all three drugs showed nearly similar adverse events.
Conclusion: In this study, after 2 weeks of follow-up, the three drugs (bilastine, levocetirizine, and rupatadine) showed significant improvement clinically, but the mean reduction in the score of symptoms and AEC was not statistically significant in the treatment of AR.
Downloads
References
Douglass JA, O’Hehir RE. 1. Diagnosis, treatment and prevention of allergic disease: The basics. Med J Aust 2006;185:228-33.
Igea JM. The history of the idea of allergy. Allergy 2013;68:966-73.
Chandrika D. Allergic rhinitis in India: An overview. Int J Otorhinolaryngol Head Neck Surg 2016;3:1-6.
Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 2008;122 Suppl 2:S1-84.
Emeryk A, Emeryk-Maksymiuk J, Janeczek K. New guidelines for the treatment of seasonal allergic rhinitis. Postepy Dermatol Alergol 2019;36:255-60.
Patel GB, Kern RC, Bernstein JA, Hae-Sim P, Peters AT. Current and future treatments of rhinitis and sinusitis. J Allergy Clin Immunol Pract 2020;8:1522-31.
Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: Evidence review. Curr Med Res Opin 2012;28:131-9.
Nettis E, Calogiuri GF, Di Leo E, Cardinale F, Macchia L, Ferrannini A, et al. Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria. J Asthma Allergy 2008;2:17-23.
Metz M, Maurer M. Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Rev Clin Immunol 2011;7:15-20.
Ellis AK, Soliman M, Steacy L, Boulay MÈ, Boulet LP, Keith PK, et al. The allergic rhinitis-clinical investigator collaborative (AR-CIC): Nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies. Allergy Asthma Clin Immunol 2015;11:16.
Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS. World Allergy Organization (WAO) White Book on Allergy: Update 2013. Milwaukee, USA: World Allergy Organization; 2013. p. 11-3, 27-31, 60-3.
Paśko P, Rodacki T, Domagała-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1-antihistamines interaction with food and alcohol-a systematic review. Biomed Pharmacother 2017;93:27-39.
Maiti R, Rahman J, Jaida J, Allala U, Palani A. Rupatadine and levocetirizine for seasonal allergic rhinitis: A comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010;136:796- 800.
Valero A, Izquierdo I, Kowalski ML, Scadding GK, Bousquet J, Mullol J. Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: A pooled responder analysis. Allergy Asthma Clin Immunol 2020;16:29.
Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47.
Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int 2017;66:97-105.
Potter PC, Paediatric Levocetirizine Study Group. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: A double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 2005;95:175-80.
Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Sharone Grace Nagur, ARSHAD, BHUVANESHWARI, SYED HAMZA QUADRI, VEENA.B, MONICA.N, VALISHETTI MANOJ KUMAR
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
